|Bid||8.90 x 1300|
|Ask||9.20 x 1000|
|Day's range||7.72 - 9.09|
|52-week range||6.15 - 20.34|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||07 Mar 2022 - 11 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.00|
AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: https://journey.ct.events/view/d2cd046c-ff2c-40ea-acdc-340df7150783 and on Lumos Pharma’s website in
Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...